Cinthia Gabriel Meireles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cinthia Gabriel Meireles has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Eliete Neves Silva Guerra
Laboratory of Oral Histopathology, Health Sciences Faculty University of Brasilia Brasilia Brazil
3 shared publications - Adriana Lofrano-Porto
Adrenal and Gonadal Diseases Clinic, Section of Endocrinology and Metabolism of the University Hospital, Graduate Program in Health Sciences, University of Brasilia, UnB, Brasília, Brazil
2 shared publications - Luciana Pinto Valadares
Unit of Osteometabolic Disorders, SARAH Network of Rehabilitation Hospitals, Brasília, Brazil
2 shared publications - Adriana Lofrano-Porto
Molecular Pharmacology Laboratory, Health Sciences Faculty, University of Brasilia, Brasilia, Brazil; Gonadal and Adrenal Diseases Clinics, University Hospital of Brasilia, University of Brasilia, Brasilia, Brazil
1 shared publication Ana Claudia Latronico
Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular, LIM42, Hospital das Clínicas, Disciplina Endocrinologia, Faculdade de Medicina da Universidade de São Paulo, SP, Brazil
1 shared publicationAna Paula Abreu
Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
1 shared publication
Latest Publications
- 23 May 2022
- Published by Wiley in Phytotherapy Research
- Vol. 36 (8) , 3032-3079
Effects of medicinal plants and natural compounds in models of prostate cancer related to sex steroids: A systematic review
Prostate cancer remains a health problem for men. Targeting androgen (AR) and estrogen (ER) receptors improves the outcomes of the disease, and many medicinal plants exert their effects by modulating these pathways. Therefore, a systematic review was conducted to identify medicinal plants and their natural compounds that may modulate the AR and/or ER pathways in cell and animal models. A search was conducted across EMBASE, LILACS, PubMed, Scopus, and Web of Science, with grey literature from Google SCHOLAR and ProQuest. Two authors independently selected eligible studies based on their titles and abstracts, and a third author resolved conflicts. Then, data from the full text of eligible studies were extracted and synthesized. In total, 75 studies were included. Results showed the effects of several different medicinal plants and natural compounds in reduction of AR and/or ER transcription and translation and AR secondary effects: cell growth reduction, induction of apoptosis, and cell cycle arrest. In animal models, tumor size reduction, increase in apoptosis, and downregulation of AR expression in tumors were also observed. No single phytochemical group concentrating molecules with anti‐AR and/or ER activity was identified. Nevertheless, several phytochemical compounds showed potential for future clinical studies in the management of the disease.
- 23 May 2022
- Published by Wiley in Phytotherapy Research
- Vol. 36 (8) , 3032-3079
Effects of medicinal plants and natural compounds in models of prostate cancer related to sex steroids: A systematic review
Prostate cancer remains a health problem for men. Targeting androgen (AR) and estrogen (ER) receptors improves the outcomes of the disease, and many medicinal plants exert their effects by modulating these pathways. Therefore, a systematic review was conducted to identify medicinal plants and their natural compounds that may modulate the AR and/or ER pathways in cell and animal models. A search was conducted across EMBASE, LILACS, PubMed, Scopus, and Web of Science, with grey literature from Google SCHOLAR and ProQuest. Two authors independently selected eligible studies based on their titles and abstracts, and a third author resolved conflicts. Then, data from the full text of eligible studies were extracted and synthesized. In total, 75 studies were included. Results showed the effects of several different medicinal plants and natural compounds in reduction of AR and/or ER transcription and translation and AR secondary effects: cell growth reduction, induction of apoptosis, and cell cycle arrest. In animal models, tumor size reduction, increase in apoptosis, and downregulation of AR expression in tumors were also observed. No single phytochemical group concentrating molecules with anti‐AR and/or ER activity was identified. Nevertheless, several phytochemical compounds showed potential for future clinical studies in the management of the disease.
- Open Access
- 25 March 2019
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (5) , 979-995
MKRN3 Mutations in Central Precocious Puberty: A Systematic Review and Meta-Analysis
MKRN3 mutations represent the most common genetic cause of central precocious puberty (CPP) but associations between genotype and clinical features have not been extensively explored. This systematic review and meta-analysis investigated genotype-phenotype associations and prevalence of MKRN3 mutations in CPP. The search was conducted in seven electronic databases (Cochrane, EMBASE, LILACS, LIVIVO, PubMed, Scopus and Web of Science) for articles published until September 4, 2018. Studies evaluating MKRN3 mutations in patients with CPP were considered eligible. A total of 22 studies, studying 880 subjects with CPP, fulfilled the inclusion criteria. 89 subjects (76 girls) were identified as harboring MKRN3 mutations. Girls, compared to boys, exhibited earlier age at pubertal onset (median 6.0 years, range 3.0-7.0, vs 8.5 years, range 5.9-9.0, Pvs 2.45 IU/L, range 0.8-13.70 IU/L, P=0.003), and bone age advancement (median 2.3 years, range -0.9-5.2 vs 1.2 years, range 0.0-2.3, P=0.01). Additional dysmorphisms were uncommon. A total of 14 studies evaluating 857 patients were included for quantitative analysis, with a pooled overall mutation prevalence of 9.0% (95% CI 0.04-0.15). Subgroup analysis showed that prevalence estimates were higher in males, familial cases and in non-Asian countries. In conclusion, MKRN3 mutations are associated with non-syndromic CPP and manifest in a gender-dimorphic manner, with girls being affected earlier. They represent a common cause of CPP in western countries, especially in boys and familial cases.
- 25 March 2019
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (5) , 979-995
Open AccessMKRN3 Mutations in Central Precocious Puberty: A Systematic Review and Meta-Analysis
MKRN3 mutations represent the most common genetic cause of central precocious puberty (CPP) but associations between genotype and clinical features have not been extensively explored. This systematic review and meta-analysis investigated genotype-phenotype associations and prevalence of MKRN3 mutations in CPP. The search was conducted in seven electronic databases (Cochrane, EMBASE, LILACS, LIVIVO, PubMed, Scopus and Web of Science) for articles published until September 4, 2018. Studies evaluating MKRN3 mutations in patients with CPP were considered eligible. A total of 22 studies, studying 880 subjects with CPP, fulfilled the inclusion criteria. 89 subjects (76 girls) were identified as harboring MKRN3 mutations. Girls, compared to boys, exhibited earlier age at pubertal onset (median 6.0 years, range 3.0-7.0, vs 8.5 years, range 5.9-9.0, Pvs 2.45 IU/L, range 0.8-13.70 IU/L, P=0.003), and bone age advancement (median 2.3 years, range -0.9-5.2 vs 1.2 years, range 0.0-2.3, P=0.01). Additional dysmorphisms were uncommon. A total of 14 studies evaluating 857 patients were included for quantitative analysis, with a pooled overall mutation prevalence of 9.0% (95% CI 0.04-0.15). Subgroup analysis showed that prevalence estimates were higher in males, familial cases and in non-Asian countries. In conclusion, MKRN3 mutations are associated with non-syndromic CPP and manifest in a gender-dimorphic manner, with girls being affected earlier. They represent a common cause of CPP in western countries, especially in boys and familial cases.
- 1 October 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 147 (1) , 167-180
Effects of metformin on endometrial cancer: Systematic review and meta-analysis
- 1 October 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 147 (1) , 167-180
Effects of metformin on endometrial cancer: Systematic review and meta-analysis
- Open Access
- 1 January 2011
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Plantas Medicinais
- Vol. 13 (3) , 359-366
Efeito embriotóxico, teratogênico e abortivo de plantas medicinais
O uso milenar de plantas medicinais mostrou ao longo dos anos, que determinadas plantas apresentam substâncias potencialmente perigosas. Do ponto de vista científico, algumas pesquisas mostraram que muitas dessas plantas possuem substâncias agressivas e por essa razão devem ser utilizadas com cuidado, respeitando seus riscos toxicológicos. Os efeitos mais preocupantes do uso indiscriminado de plantas medicinais são embriotóxico, teratogênico e abortivo, uma vez, que os constituintes da planta podem atravessar a placenta, chegar ao feto e gerar um desses efeitos. Este estudo objetiva fornecer uma listagem das principais plantas medicinais que tenham efeitos embriotóxicos, teratogênicos e abortivos comprovados, conhecendo as partes da planta utilizadas e seus respectivos nomes científicos, com a finalidade de alertar gestantes quanto aos riscos de seu uso. Realizou-se buscas nas bases eletrônicas de dados SciELO, PubMed, MEDLINE, LILACS, CAPES e Google acadêmico. Nos resultados encontrados, plantas como Arnica (Arnica montana), Artemísia (Artemisia vulgaris), Arruda (Ruta chalepensis/ Ruta graveolens), Barbatimão (Stryphnodendron polyphyllum), Boldo (Vernonia condensata) dentre outras, podem vir a gerar um desses efeitos. A partir deste estudo comprova-se que para a maioria das plantas medicinais não há dados a respeito da segurança de seu uso durante a gravidez.
- 1 January 2011
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Plantas Medicinais
- Vol. 13 (3) , 359-366
Open AccessEfeito embriotóxico, teratogênico e abortivo de plantas medicinais
O uso milenar de plantas medicinais mostrou ao longo dos anos, que determinadas plantas apresentam substâncias potencialmente perigosas. Do ponto de vista científico, algumas pesquisas mostraram que muitas dessas plantas possuem substâncias agressivas e por essa razão devem ser utilizadas com cuidado, respeitando seus riscos toxicológicos. Os efeitos mais preocupantes do uso indiscriminado de plantas medicinais são embriotóxico, teratogênico e abortivo, uma vez, que os constituintes da planta podem atravessar a placenta, chegar ao feto e gerar um desses efeitos. Este estudo objetiva fornecer uma listagem das principais plantas medicinais que tenham efeitos embriotóxicos, teratogênicos e abortivos comprovados, conhecendo as partes da planta utilizadas e seus respectivos nomes científicos, com a finalidade de alertar gestantes quanto aos riscos de seu uso. Realizou-se buscas nas bases eletrônicas de dados SciELO, PubMed, MEDLINE, LILACS, CAPES e Google acadêmico. Nos resultados encontrados, plantas como Arnica (Arnica montana), Artemísia (Artemisia vulgaris), Arruda (Ruta chalepensis/ Ruta graveolens), Barbatimão (Stryphnodendron polyphyllum), Boldo (Vernonia condensata) dentre outras, podem vir a gerar um desses efeitos. A partir deste estudo comprova-se que para a maioria das plantas medicinais não há dados a respeito da segurança de seu uso durante a gravidez.